News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,119 Results
Type
Article (39552)
Company Profile (310)
Press Release (651257)
Section
Business (204830)
Career Advice (2011)
Deals (35485)
Drug Delivery (91)
Drug Development (81055)
Employer Resources (168)
FDA (16133)
Job Trends (14867)
News (345930)
Policy (32563)
Tag
Academia (2548)
Alliances (49536)
Alzheimer's disease (1270)
Approvals (16097)
Artificial intelligence (146)
Bankruptcy (356)
Best Places to Work (11606)
Biotechnology (217)
Breast cancer (191)
Cancer (1393)
Cardiovascular disease (110)
Career advice (1677)
Cell therapy (287)
Clinical research (64855)
Collaboration (492)
Compensation (271)
COVID-19 (2558)
C-suite (110)
Data (1397)
Diabetes (178)
Diagnostics (6192)
Earnings (85036)
Employer resources (146)
Events (110573)
Executive appointments (406)
FDA (16834)
Funding (444)
Gene therapy (199)
GLP-1 (603)
Government (4347)
Healthcare (18730)
Infectious disease (2651)
Inflammatory bowel disease (115)
Interviews (309)
IPO (16387)
Job creations (3660)
Job search strategy (1430)
Layoffs (425)
Legal (7901)
Lung cancer (201)
Lymphoma (99)
Manufacturing (208)
Medical device (13225)
Medtech (13230)
Mergers & acquisitions (19282)
Metabolic disorders (463)
Neuroscience (1597)
NextGen Class of 2024 (6535)
Non-profit (4479)
Northern California (1727)
Obesity (262)
Opinion (187)
Patents (122)
People (56802)
Phase I (20195)
Phase II (28567)
Phase III (21282)
Pipeline (515)
Postmarket research (2561)
Preclinical (8577)
Radiopharmaceuticals (236)
Rare diseases (266)
Real estate (5937)
Regulatory (21763)
Research institute (2317)
Resumes & cover letters (350)
Southern California (1483)
Startups (3614)
United States (15440)
Vaccines (566)
Weight loss (183)
Date
Last 7 days (171)
Last 30 days (1601)
Last 365 days (34637)
2025 (91)
2024 (35371)
2023 (40182)
2022 (51288)
2021 (55836)
2020 (54158)
2019 (46645)
2018 (35125)
2017 (32224)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27526)
Location
Africa (716)
Arizona (196)
Asia (37510)
Australia (6139)
California (3893)
Canada (1475)
China (324)
Colorado (174)
Connecticut (180)
Europe (80361)
Florida (548)
Georgia (136)
Illinois (394)
Indiana (228)
Maryland (641)
Massachusetts (3006)
Michigan (175)
Minnesota (296)
New Jersey (1123)
New York (1105)
North Carolina (747)
Northern California (1727)
Ohio (150)
Pennsylvania (942)
South America (1095)
Southern California (1483)
Texas (564)
Utah (108)
Washington State (404)
691,119 Results for "sangamo biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
Regulatory
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy candidate, eliminating the need for an additional registrational study and potentially shortening the time-to-market by three years.
October 23, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
July 31, 2024
·
3 min read
·
Tyler Patchen
Business
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics, Inc., a genomic medicines company, reported business highlights and first quarter 2024 financial results.
May 9, 2024
·
17 min read
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
December 19, 2024
·
7 min read
Press Releases
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
December 19, 2024
·
7 min read
Deals
Cash-Strapped Sangamo Gets Lifeline from Genentech in Potential $1.9B Neuro Deal
Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.
August 6, 2024
·
2 min read
·
Tyler Patchen
Business
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
May 2, 2024
·
1 min read
Press Releases
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
December 31, 2024
·
10 min read
Drug Development
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics, Inc. today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
May 9, 2024
·
4 min read
1 of 69,112
Next
